PORTLAND, OR - Researchers have analyzed and reported on a sweeping data set on the Death with Dignity Act, Oregon's first-in-the-nation law that allows physicians to provide terminally ill patients with a lethal dose of medication.
The Death with Dignity Act became Oregon law in 1997, and today, the states of Washington, Vermont, Colorado, and California have passed similar legislation, as has the District of Columbia. Assisted dying is also legal in Montana through a state Supreme Court ruling. According to the non-profit Death with Dignity National Center, legislators in at least 20 other states are expected to consider assisted dying bills this year.
SWOG, part of the National Cancer Institute's National Clinical Trials Network, conducted the research using data provided by the Oregon Health Authority, results of which appear in JAMA Oncology . For California and Colorado, where assisted dying laws went into effect in 2016, and in the District of Columbia, where the law took effect in 2017, Oregon's experience offers a potential preview:
Dr. Charles D. Blanke is SWOG group chair and lead author of the JAMA Oncology article. An oncologist and professor of medicine at Oregon Health & Science University, Blanke said he was surprised at the reasons people cited for opting for assisted dying. Untreatable pain was not the main reason people used the law, Blanke said. The most common reasons were the loss of autonomy and dignity and the inability to enjoy life.
"You can't easily palliate loss of dignity," Blanke said. "Patients' end of life concerns can't always be addressed through direct medical treatment."
Blanke said the research points up rich areas for future study. "If we knew more about how patients make decisions about assisted dying," he said, "we might be able to use that information data to ease end-of-life concerns and either delay the use of assisted dying or reduce the numbers altogether."
###
The study team also included Michael LeBlanc, Ph.D. of Fred Hutchinson Cancer Research Center; Dr. Dawn Hershman of Columbia University; Dr. Lee Ellis of University of Texas MD Anderson Cancer Center; and Dr. Frank Meyskens of the University of California Irvine.
All authors are supported by funding from the National Cancer Institute, but this funding was not used in support of this manuscript and may not represent the official views of the National Cancer Institute or National Institute of Health.
SWOG designs and conducts cancer clinical trials as part of the publicly funded National Cancer Institute's National Clinical Trials Network and the NCI Community Oncology Research Program and is a major part of the cancer research infrastructure in the U.S. and the world. SWOG has over 12,000 members at more than 1,000 sites in 46 states and six foreign countries. Founded in 1956, SWOG trials have led to the approval of 14 cancer drugs, changed more than 100 standards of cancer care, and saved more than 2 million years of human life. SWOG is headquartered at the Knight Cancer Institute at Oregon Health & Science University in Portland, Ore., and its statistics and data management center is based at Fred Hutchinson Cancer Research Center in Seattle. SWOG's operations office is located in San Antonio, Texas. Learn more at swog.org .
JAMA Oncology